Axiom signs deal with medical company to do diabetes monitor research on its next manned mission to ISS
Axiom today announced it has signed a deal with the medical company Burjeel Holdings to fly and test a glucose monitor during its May 2025 AX-4 manned mission to ISS.
The Ax-4 mission will utilize Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with insulin-dependent diabetes.The comprehensive preflight, inflight, and post flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth.
Testing the behavior of CGMs and insulin delivery technologies in microgravity and with circadian rhythm disruption is expected to advance the understanding of how such innovations can improve diabetes monitoring and care in remote or under served areas on Earth. Experts say this research will lay the groundwork for managing diabetes in isolated locations, such as oil rigs, deserts, or rural regions.
These tests will also make it possible for people who have diabetes to go into space. For Axiom, this will help widen its customer base. For Burjeel it proves its monitors can work in many remote and hostile environments, also widening its customer base.
Hat tip BtB’s stringer Jay, who adds that “This is cool since this is two companies and no NASA/government involvement.”
Axiom today announced it has signed a deal with the medical company Burjeel Holdings to fly and test a glucose monitor during its May 2025 AX-4 manned mission to ISS.
The Ax-4 mission will utilize Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with insulin-dependent diabetes.The comprehensive preflight, inflight, and post flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth.
Testing the behavior of CGMs and insulin delivery technologies in microgravity and with circadian rhythm disruption is expected to advance the understanding of how such innovations can improve diabetes monitoring and care in remote or under served areas on Earth. Experts say this research will lay the groundwork for managing diabetes in isolated locations, such as oil rigs, deserts, or rural regions.
These tests will also make it possible for people who have diabetes to go into space. For Axiom, this will help widen its customer base. For Burjeel it proves its monitors can work in many remote and hostile environments, also widening its customer base.
Hat tip BtB’s stringer Jay, who adds that “This is cool since this is two companies and no NASA/government involvement.”